Fingerprint
Untersuchen Sie die Forschungsthemen von „Erdafitinib in BCG-treated high-risk non-muscle-invasive bladder cancer“. Zusammen bilden sie einen einzigartigen Fingerprint.- sortieren
- Gewicht:
- Alphabetisch
Erdafitinib in BCG-treated high-risk non-muscle-invasive bladder cancer
THOR-2 Cohort 1 Investigators
- University of Sheffield
- Sheffield Teaching Hospitals NHS Foundation Trust
- Peter Maccallum Cancer Centre
- AP-HP
- Université Paris-Saclay
- Faculty of Medicine, University of Tsukuba
- Universitat Autònoma de Barcelona
- University of Southern California
- Sirio Libanes Hospital
- Fondazione IRCCS Istituto Nazionale dei Tumori, Milan
- East and North Hertfordshire NHS Trust
- University of Hertfordshire
- Janssen Research and Development
- Rush University Medical Center
Publikation: Beitrag in Fachzeitschrift › Artikel › Begutachtung
14
Zitate
(Scopus)